Physician profile
Gary Luckman
NPI 1225001472
$6,102.95
in general payments reported to CMS, 2019-2025
30 companies · $912 in 2025
The $912 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,371 · 2020: $925 · 2021: $448 · 2022: $467 · 2023: $759 · 2024: $1,220 · 2025: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,807 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,807.19 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,693.08 | 2019-2025 | |
| Janssen Biotech, INC. | $954.24 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $508.60 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $341.61 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Celgene Corporation | $262.18 | 2021-2024 | Zeposia |
| Intra-Sana Laboratories | $250.00 | 2020 | |
| Janssen Scientific Affairs, LLC | $241.76 | 2019 | |
| Madrigal Pharmaceuticals | $225.09 | 2024-2025 | Resmetirom, Rezdiffra |
| Lilly USA, LLC | $184.33 | 2022-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $175.07 | 2019-2025 | Ocaliva |
| Pfizer INC. | $154.90 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $152.05 | 2020-2023 | Linzess |
| Ardelyx, INC. | $142.34 | 2022-2025 | Ibsrela |
| Ucb, INC. | $116.62 | 2019 | |
| Phathom Pharmaceuticals, INC. | $105.56 | 2024-2025 | Voquezna |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $104.77 | 2025 | Iqirvo |
| Genzyme Corporation | $98.82 | 2025 | |
| Aimmune Therapeutics, INC. | $88.25 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $56.96 | 2021-2023 | |
| Evoke Pharma, INC. | $47.10 | 2020-2024 | Gimoti |
| Daiichi Sankyo INC. | $33.65 | 2019-2021 | |
| Allergan, INC. | $31.51 | 2019 | |
| Fresenius Kabi USA, LLC | $21.27 | 2023 | |
| Shire North American Group INC | $19.16 | 2019 | |
| Shionogi INC | $18.66 | 2019 | |
| Merck Sharp & Dohme LLC | $17.50 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $17.30 | 2022-2024 | Jumbo Biopsy Forcep, Dat Device |
| Redhill Biopharma INC. | $16.41 | 2020 | |
| Alfasigma USA, INC. | $16.17 | 2020 | |
| Janssen Pharmaceuticals, INC | $7.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Luckman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.